EpiCast Report: Hemophilia - Epidemiology Forecast to 2024

Description: EpiCast Report: Hemophilia - Epidemiology Forecast to 2024

Summary

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In 2014, the 9MM had 60,671 diagnosed prevalent cases of hemophilia A and hemophilia B, around 28% of which occurred in the US. The diagnosed prevalent cases of hemophilia in the 9MM are expected to increase slightly to 61,954 cases by 2024. The US will have the largest proportion of diagnosed prevalent cases of hemophilia A and hemophilia B in the 9MM in 2024 at 29.05%. Because hemophilia is an inherited condition, it requires lifelong treatment. Given the increase in the prevalence of hypertension, with advancing age and increasing life expectancy in hemophiliacs due to advances in treatment, the challenges faced by hemophiliacs and the need for more supportive treatments and care will increase in the near future.

GlobalData epidemiologists forecast the epidemiological trend for hemophilia using data from the WFH Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization (NMO), allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

- The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Argentina, and China). In addition, the report includes a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia, segmented by type (A and B), sex, and age (starting at ages 0 years) in these markets.
- The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
- Identify the hemophilia type that is most important to your marketing plans.

Contents:

1.1 List of Tables

1.2 List of Figures

2 Introduction
4.2.2 Reviewers

4.2.3 Global Director of Epidemiology and Health Policy

4.2.4 Global Head of Healthcare

4.3 About Us

4.4 About EpiCast

4.5 Disclaimer

1.1 List of Tables

Table 1: Relationship of Bleeding Severity with Clotting Factor Level

Table 2: Hemophilia - Risk Factors and Comorbidities

Table 3: 9MM, Diagnosed Prevalence of Hemophilia A (per 100,000 Population), Both Sexes, All Ages, 2004-2013

Table 4: 9MM, Diagnosed Prevalence of Hemophilia B (per 100,000 Population), Both Sexes, All Ages, 2004-2013

Table 5: 9MM, Sources and Diagnosed Prevalence Data for Hemophilia A and B

Table 6: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024

Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2014

Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2014

Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024

Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2014

Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2014

Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2014-2024

Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, Row (%), 2014

1.2 List of Figures

Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024

Figure 2: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2014

Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2014

Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (per 100,000 Population), by Sex, 2014

Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024

Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2014

Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2014

Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2014
Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2014-2024

Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, 2014

Ordering:  
Order Online - [http://www.researchandmarkets.com/reports/3455804/](http://www.researchandmarkets.com/reports/3455804/)  
Order by Fax - using the form below  
Order by Post - print the order form below and send to  
Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: EpiCast Report: Hemophilia - Epidemiology Forecast to 2024
Web Address: http://www.researchandmarkets.com/reports/3455804/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 3995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 7990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 11985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World